Staying at a lower dose for longer before moving up may not be a bad idea and is completely normal
Y., Risbud, S
Non-approved Therapies for Obesity Incretin-based Treatments Since the isolation of the peptide exendin-4 from Heloderma suspectum (Gila Monster) lizard venom in 1992 [25], several drugs that manipulate the incretin axis have been produced and approved for use in people with T2D including exenatide (2005), liraglutide (2009), lixisenatide (2013), albiglutide (2014, withdrawn 2017), dulaglutide (2014) and semaglutide (2017) [26]
Moreover, infected diabetic ulcers significantly heighten the risk of disability and mortality among these patients (Armstrong et al., 2020)
b) Thyroid C-cell tumors: Animal studies have shown an increased incidence of thyroid C-cell tumors (benign and malignant) with long-term use of some GLP-1 receptor agonists
For instance, a glycoprotein ES-62 secreted by Acanthocheilonema viteae can protect against rheumatoid arthritis, systemic lupus erythematosus, and airway hyper-responsiveness is mainly attributed to the covalently-bonded phosphorylcholine moieties (Pineda et al., 2014
